Business Context and Reporting Period
Company: Aytu BioScience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 18, 2019
Event: Closing of the "Armistice Transaction," a material definitive agreement previously disclosed in the February 7, 2019 Form 10-Q and approved by stockholders on April 12, 2019.
Key Financial Metrics and Transaction Details
This filing details a debt-for-equity exchange rather than standard operating financial results. The filing text does not provide revenue, profit, cash flow, or margin data.
- Debt Resolution: Cancellation of a Note held by Armistice Capital, satisfying all principal and interest owed.
- Equity Issued:
- 3,120,064 shares of Common Stock.
- 2,751,148 shares of Series E Convertible Preferred Stock.
- Warrants Issued: One Common Stock Purchase Warrant exercisable for 4,403,409 shares of Common Stock at an exercise price of $1.00 per share.
- Liquidity Impact: The transaction eliminated debt obligations without immediate cash outflow, though it increased the potential share count.
Material Changes Versus Prior Period
The primary material change is the conversion of a debt instrument into equity and warrant securities following stockholder approval. This alters the company's capital structure by:
- Removing the specific Note liability from the balance sheet.
- Increasing the number of authorized and outstanding equity instruments (Common Stock, Series E Preferred, and Warrants).
- Introducing new voting and dividend restrictions tied to the Series E Preferred Stock.
Guidance, Outlook, and Material Terms
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operational performance. However, it outlines significant terms affecting future capital structure:
- Series E Preferred Stock:
- Conversion: Convertible 1:1 into Common Stock, subject to a 40% beneficial ownership limitation.
- Dividends: No dividends payable on Common Stock unless dividends are paid on Series E Preferred Stock on an as-converted basis.
- Voting: Generally no voting rights, but holders must approve changes to their rights, charter amendments affecting them, or increases in authorized Series E shares.
- Liquidation: Participates on an as-converted basis with Common Stock holders.
- Exchange Warrant:
- Term: Expires five years from issuance.
- Anti-Dilution: Includes broad anti-dilution protection for stock splits, dividends, and rights offerings.
- Limitation: Subject to a 40% beneficial ownership limitation upon exercise.
- Risks: Potential dilution to existing shareholders if the Series E Preferred Stock or Warrants are exercised.
Investor Verification Checklist
- Verify the exact amount of principal and interest debt extinguished by reviewing the February 7, 2019 Form 10-Q.
- Confirm the total number of shares outstanding post-transaction to assess immediate dilution.
- Review the Certificate of Designation (Exhibit 10.1) for specific voting thresholds and dividend mechanics.
- Monitor the 40% beneficial ownership limitation to understand potential restrictions on future conversions or warrant exercises.
- Check subsequent filings for any cashless exercise provisions or adjustments to the warrant exercise price.